A recombinant immunotoxin derived from a humanized epithelial cell adhesion molecule-specific single-chain antibody fragment has potent and selective antitumor activity

Clinical Cancer Research

Volumn 9, Issue 7, 2003, Pages 2837-2848

  Di Paolo, Claudio ^a   Willuda, Jörg ^b,d   Kubetzko, Susanne ^b   Lauffer, Ikar ^a   Tschudi, Dominique ^a   Waibel, Robert ^c   Plückthun, Andreas ^b   Stahel, Rolf A ^a   Zangemeister Wittke, Uwe ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY OF ZURICH   (Switzerland)

^c PAUL SCHERRER INSTITUTE   (Switzerland)

^d BAYER PHARMA AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CELL ADHESION MOLECULE; IMMUNOTOXIN; RECOMBINANT ANTIBODY; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN BINDING; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL ASSAY; COLON; CONTROLLED STUDY; CYTOPATHOLOGY; DRUG CYTOTOXICITY; DRUG POTENCY; DRUG SCREENING; DRUG SPECIFICITY; HUMAN; HUMAN CELL; LUNG PARENCHYMA; MOUSE; NONHUMAN; NUDE MOUSE; PHARMACEUTICAL ENGINEERING; PHARMACOGENETICS; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; THERMOSTABILITY; TUMOR LOCALIZATION; TUMOR XENOGRAFT;

ADP RIBOSE TRANSFERASES; ANIMALS; ANTINEOPLASTIC AGENTS; BACTERIAL TOXINS; CELL ADHESION MOLECULES; CELL DIVISION; CELL LINE, TUMOR; CHROMATOGRAPHY, GEL; DOSE-RESPONSE RELATIONSHIP, DRUG; EPITHELIAL CELLS; EXOTOXINS; FEMALE; FLOW CYTOMETRY; GENETIC VECTORS; HUMANS; IMMUNOGLOBULIN FRAGMENTS; IMMUNOTOXINS; INHIBITORY CONCENTRATION 50; MICE; MICE, INBRED C57BL; MICE, NUDE; MODELS, MOLECULAR; NEOPLASM TRANSPLANTATION; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT PROTEINS; TIME FACTORS; VIRULENCE FACTORS;

EID: 0037478897     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (63)

1. Gottesman, M. M., and Pastan, I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu. Rev. Biochem., 62: 385-427, 1993.
2. Pai, L. H., and Pastan, I. Clinical trials with Pseudomonas exotoxin immunotoxins. Curr. Top. Microbiol. Immunol., 234: 83-96, 1998.
3. Eccles, S. A. Monoclonal antibodies targeting cancer: 'magic bullets' or just the trigger? Breast Cancer Res., 3: 86-90, 2001.
4. Penichet, M. L., and Morrison, S. L. Antibody-cytokine fusion proteins for the therapy of cancer. J. Immunol. Methods, 248: 91-101, 2001.
5. Balzar, M., Winter, M. J., de Boer, C. J., and Litvinov, S. V. The biology of the 17-1A antigen (Ep-CAM). J. Mol. Med., 77: 699-712, 1999.
6. Beverley, P. C., Olabiran, Y., Ledermann, J. A., Bobrow, L. G., and Souhami, R. L. Results of the central data analysis. Br. J. Cancer Suppl., 14: 10-19, 1991.
7. Riethmüller, G., Holz, E., Schlimok, G., Schmiegel, W., Raab, R., Hoffken, K., Gruber, R., Funke, I., Pichlmaier, H., Hirche, H., Buggisch, P., Witte, J., and Pichlmayr, R. Monoclonal antibody therapy for resected Dukes' C colorectal cancer: seven-year outcome of a multicenter randomized trial. J. Clin. Oncol., 16: 1788-1794, 1998.
8. Braun, S., Hepp, F., Kentenich, C. R., Janni, W., Pantel, K., Riethmuller, G., Willgeroth, F., and Sommer, H. L. Monoclonal antibody therapy with edrecolomab in breast cancer patients: monitoring of elimination of disseminated cytokeratin-positive tumor cells in bone marrow. Clin. Cancer Res., 5: 3999-4004, 1999.
9. Mellstedt, H., Fagerberg, J., Frodin, J. E., Hjelm-Skog, A. L., Liljefors, M., Markovic, K., Mosolits, S., and Ragnhammar, P. Ga733/EpCAM as a target for passive and active specific immunotherapy in patients with colorectal carcinoma. Ann. N. Y. Acad. Sci., 910: 254-261, 2000.
10. McLaughlin, P. M., Harmsen, M. C., Dokter, W. H., Kroesen, B. J., van der, M. H., Brinker, M. G., Hollema, H., Ruiters, M. H., Buys, C. H., and de Leij, L. F. The epithelial glycoprotein 2 (EGP-2) promoter-driven epithelial-specific expression of EGP-2 in transgenic mice: a new model to study carcinoma-directed immunotherapy. Cancer Res., 61: 4105-4111, 2001.
11. Litvinov, S. V., Bakker, H. A., Gourevitch, M. M., Velders, M. P., and Warnaar, S. O. Evidence for a role of the epithelial glycoprotein 40 (Ep-CAM) in epithelial cell-cell adhesion. Cell Adhes. Commun., 2: 417-428, 1994.
12. Litvinov, S. V., van Driel, W., van Rhijn, C. M., Bakker, H. A., van Krieken, H., Fleuren, G. J., and Warnaar, S. O. Expression of Ep-CAM in cervical squamous epithelia correlates with an increased proliferation and the disappearance of markers for terminal differentiation. Am. J. Pathol., 148: 865-875, 1996.
13. Litvinov, S. V., Balzar, M., Winter, M. J., Bakker, H. A., Briairede Bruijn, I. H., Prins, F., Fleuren, G. J., and Warnaar, S. O. Epithelial cell adhesion molecule (Ep-CAM) modulates cell-cell interactions mediated by classic cadherins. J. Cell Biol., 139: 1337-1348, 1997.
14. Kosterink, J. G., de Jonge, M. W., Smit, E. F., Piers, D. A., Kengen, R. A., Postmus, P. E., Shochat, D., Groen, H. J., The, H. T., and de Leij, L. Pharmacokinetics and scintigraphy of indium-111-DTPA-MOC-31 in small-cell lung carcinoma. J. Nucl. Med., 36: 2356-2362, 1995.
15. 99mTc-labeled monoclonal antibody. Clin. Nucl. Med., 17: 431-438, 1992.
16. Hjelm, S. A., Ragnhammar, P., Fagerberg, J., Frodin, J., Goldinger, M., Koldestam, H., Liljefors, M., Nilsson, B., Shetye, J., Wersall, P., and Mellstedt, H. Clinical effects of monoclonal antibody 17-1A combined with granulocyte/macrophage-colony-stimulating factor and interleukin-2 for treatment of patients with advanced colorectal carcinoma. Cancer Immunol. Immunother., 48: 463-470, 1999.
17. Derbyshire, E. J., Henry, R. V., Stahel, R. A., and Wawrzynczak, E. J. Potent cytotoxic action of the immunotoxin SWA11-ricin A chain against human small cell lung cancer cell lines. Br. J. Cancer, 66: 444-451, 1992.
18. Zimmermann, S., Wels, W., Froesch, B. A., Gerstmayer, B., Stahel, R. A., and Zangemeister-Wittke, U. A novel immunotoxin recognising the epithelial glycoprotein-2 has potent antitumoural activity on chemotherapy-resistant lung cancer. Cancer Immunol. Immunother., 44: 1-9, 1997.
19. Elias, D. J., Hirschowitz, L., Kline, L. E., Kroener, J. F., Dillman, R. O., Walker, L. E., Robb, J. A., and Timms, R. M. Phase I clinical comparative study of monoclonal antibody KS1/4 and KS1/4-methotrexate immunconjugate in patients with non-small cell lung carcinoma. Cancer Res., 50: 4154-4159, 1990.
20. Kreitman, R. J., and Pastan, I. Accumulation of a recombinant immunotoxin in a tumor in vivo: fewer than 1000 molecules per cell are sufficient for complete responses. Cancer Res., 58: 968-975, 1998.
21. Perentesis, J. P., Miller, S. P., and Bodley, J. W. Protein toxin inhibitors of protein synthesis. Biofactors, 3: 173-184, 1992.
22. Brinkmann, U., Pai, L. H., FitzGerald, D. J., Willingham, M., and Pastan, I. B3(Fv)-PE38KDEL, a single-chain immunotoxin that causes complete regression of a human carcinoma in mice. Proc. Natl. Acad. Sci. USA, 88: 8616-8620, 1991.
23. Wels, W., Harwerth, I. M., Mueller, M., Groner, B., and Hynes, N. E. Selective inhibition of tumor cell growth by a recombinant single-chain antibody-toxin specific for the erbB-2 receptor. Cancer Res., 52: 6310-6317, 1992.
24. Kreitman, R. J., Bailon, P., Chaudhary, V. K., FitzGerald, D. J., and Pastan, I. Recombinant immunotoxins containing anti-Tac(Fv) and derivatives of Pseudomonas exotoxin produce complete regression in mice of an interleukin-2 receptor-expressing human carcinoma. Blood, 83: 426-434, 1994.
25. Wels, W., Beerli, R., Hellmann, P., Schmidt, M., Marte, B. M., Kornilova, E. S., Hekele, A., Mendelsohn, J., Groner, B., and Hynes, N. E. EGF receptor and p185erbB-2-specific single-chain antibody toxins differ in their cell-killing activity on tumor cells expressing both receptor proteins. Int. J. Cancer, 60: 137-144, 1995.
26. Zangemeister-Wittke, U., and Wels, W. Targeted cytotoxicity: antibody-drug and antibody-toxin conjugates. In: S. Matzko and A. Rolf (eds.), Antibodies in Diagnosis and Therapy: Technologies, Mechanism and Clinical Data, pp. 81-114. Amsterdam: Harwood Academic Publishers, 1999.
27. Siegall, C. B., Liggitt, D., Chace, D., Mixan, B., Sugai, J., Davidson, T., and Steinitz, M. Characterization of vascular leak syndrome induced by the toxin component of Pseudomonas exotoxin-based immunotoxins and its potential inhibition with nonsteroidal anti-inflammatory drugs. Clin. Cancer Res., 3: 339-345, 1997.
28. Kreitman, R. J. Immunotoxins. Expert. Opin. Pharmacother., 1: 1117-1129, 2000.
29. Onda, M., Willingham, M., Wang, Q. C., Kreitman, R. J., Tsutsumi, Y., Nagata, S., and Pastan, I. Inhibition of TNF-α produced by Kupffer cells protects against the nonspecific liver toxicity of immunotoxin anti-Tac(Fv)-PE38. LMB-2. J. Immunol., 165: 7150-7156, 2000.
30. FitzGerald, D., Pastan, I., and Robertus, J. Clinical applications of immunotoxins. Introduction. Curr. Top. Microbiol. Immunol., 234: 1-11, 1998.
31. Kuska, B. First responses seen in cancer patients to a recombinant immunotoxin. J. Natl. Cancer Inst. (Bethesda), 91: 1997, 1999.
32. Debinski, W., and Pastan, I. Recombinant F(ab′) C242- Pseudomonas exotoxin, but not the whole antibody-based immunotoxin, causes regression of a human colorectal tumor xenograft. Clin. Cancer Res., 1: 1015-1022, 1995.
33. Chaudhary, V. K., Queen, C., Junghans, R. P., Waldmann, T. A., FitzGerald, D. J., and Pastan, I. A recombinant immunotoxin consisting of two antibody variable domains fused to Pseudomonas exotoxin. Nature (Lond.), 339: 394-397, 1989.
34. Benhar, I., and Pastan, I. Characterization of B1(Fv)PE38 and B1(dsFv)PE38: single-chain and disulfide-stabilized Fv immunotoxins with increased activity that cause complete remissions of established human carcinoma xenografts in nude mice. Clin. Cancer Res., 1: 1023-1029, 1995.
35. Reiter, Y., Wright, A. F., Tonge, D. W., and Pastan, I. Recombinant single-chain and disulfide-stabilized Fv-immunotoxins that cause complete regression of a human colon cancer xenograft in nude mice. Int. J. Cancer, 67: 113-123, 1996.
36. Schmidt, M., and Wels, W. Targeted inhibition of tumour cell growth by a bispecific single-chain toxin containing an antibody domain and TGF-α. Br. J. Cancer, 74: 853-862, 1996.
37. Kreitman, R. J. Immunotoxins in cancer therapy. Curr. Opin. Immunol., 11: 570-578, 1999.
38. Willuda, J., Honegger, A., Waibel, R., Schubiger, P. A., Stahel, R., Zangemeister-Wittke, U., and Plückthun, A. High thermal stability is essential for tumor targeting of antibody fragments: engineering of a humanized anti-epithelial glycoprotein-2 (epithelial cell adhesion molecule) single-chain Fv fragment. Cancer Res., 59: 5758-5767, 1999.
39. Ge, L., Knappik, A., Pack, P., Freund, C., and Plückthun, A. Expressing antibodies in Escherichia coli. In: C. A. K. Borrebaeck (ed.), Antibody Engineering, pp. 229-261. Oxford: Oxford University Press, 1995.
40. Bass, S., Gu, Q., and Christen, A. Multicopy suppressors of prc mutant Escherichia coli include two HtrA (DegP) protease homologs (HhoAB), DksA, and a truncated R1pA. J. Bacteriol., 178: 1154-1161, 1996.
41. Plückthun, A., Krebber, A., Krebber, C., Horn, U., Knüpfer, U., Wenderoth, R., Nieba, L., Proba, K., and Riesenberg, D. Producing antibodies in Escherichia coli: from PCR to fermentation. In: J. McCafferty, H. R. Hoogenboom, and D. J. Chiswell (eds.), Antibody Engineering, pp. 203-252. Oxford: IRL Press, 1996.
42. Waibel, R., Alberto, R., Willuda, J., Finnern, R., Schibli, R., Stichelberger, A., Egli, A., Abram, U., Mach, J. P., Plückthun, A., and Schubiger, P. A. Stable one-step technetium-99m labeling of His-tagged recombinant proteins with a novel Tc(I)-carbonyl complex. Nat. Biotechnol., 17: 897-901, 1999.
43. Lindmo, T., Boven, E., Cuttitta, F., Fedorko, J., and Bunn, P. A., Jr. Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J. Immunol. Methods, 72: 77-89, 1984.
44. Mosmann, T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods, 65: 55-63, 1983.
45. Seetharam, S., Chaudhary, V. K., FitzGerald, D., and Pastan, I. Increased cytotoxic activity of Pseudomonas exotoxin and two chimeric toxins ending in KDEL. J. Biol. Chem., 266: 17376-17381, 1991.
46. Schümann, J., Angermüller, S., Bang, R., Lohoff, M., and Tiegs, G. Acute hepatotoxicity of Pseudomonas aeruginosa exotoxin A in mice depends on T cells and TNF. J. Immunol., 161: 5745-5754, 1998.
47. Schümann, J., Wolf, D., Pahl, A., Brune, K., Papadopoulos, T., van Rooijen, N., and Tiegs, G. Importance of Kupffer cells for T-cell-dependent liver injury in mice. Am. J. Pathol., 157: 1671-1683, 2000.
48. Oppenheimer, N. J., and Bodley, J. W. Diphtheria toxin. Site and configuration of ADP-ribosylation of diphthamide in elongation factor-2. J. Biol. Chem., 256: 8579-8581, 1981.
49. Phan, L. D., Perentesis, J. P., and Bodley, J. W. Saccharomyces cerevisiae elongation factor-2. Mutagenesis of the histidine precursor of diphthamide yields a functional protein that is resistant to diphtheria toxin. J. Biol. Chem., 268: 8665-8668, 1993.
50. Foley, B. T., Moehring, J. M., and Moehring, T. J. Mutations in the elongation factor 2 gene which confer resistance to diphtheria toxin and Pseudomonas exotoxin A. Genetic and biochemical analyses. J. Biol. Chem., 270: 23218-23225, 1995.
51. Kreitman, R. J., Wilson, W. H., Robbins, D., Margulies, I., Stetler-Stevenson, M., Waldmann, T. A., and Pastan, I. Responses in refractory hairy cell leukemia to a recombinant immunotoxin. Blood, 94: 3340-3348, 1999.
52. Kreitman, R. J., Wilson, W. H., White, J. D., Stetler-Stevenson, M., Jaffe, E. S., Giardina, S., Waldmann, T. A., and Pastan, I. Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies. J. Clin. Oncol., 18: 1622-1636, 2000.
53. Kreitman, R. J., Wilson, W. H., Bergeron, K., Raggio, M., Stetler-Stevenson, M., FitzGerald, D. J., and Pastan, I. Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. N. Engl. J. Med., 345: 241-247, 2001.
54. Chang, K., Pai, L. H., Batra, J. K., Pastan, I., and Willingham, M. C. Characterization of the antigen (CAK1) recognized by monoclonal antibody K1 present on ovarian cancers and normal mesothelium. Cancer Res., 52: 181-186, 1992.
55. Benhar, I., Reiter, Y., Pai, L. H., and Pastan, I. Administration of disulfide-stabilized Fv-immunotoxins B1(dsFv)-PE38 and B3(dsFv)-PE38 by continuous infusion increases their efficacy in curing large tumor xenografts in nude mice. Int. J. Cancer, 62: 351-355, 1995.
56. Pai, L. H., Wittes, R., Setser, A., Willingham, M. C., and Pastan, I. Treatment of advanced solid tumors with immunotoxin LMB-1: an antibody linked to Pseudomonas exotoxin. Nat. Med., 2: 350-353, 1996.
57. Kuan, C. T., Pai, L. H., and Pastan, I. Immunotoxins containing Pseudomonas exotoxin that target LeY damage human endothelial cells in an antibody-specific mode: relevance to vascular leak syndrome. Clin. Cancer Res., 1: 1589-1594, 1995.
58. Myklebust, A. T., Godal, A., Pharo, A., Juell, S., and Fodstad, O. Eradication of small cell lung cancer cells from human bone marrow with immunotoxins. Cancer Res., 53: 3784-3788, 1993.
59. Azemar, M., Schmidt, M., Arlt, F., Kennel, P., Brandt, B., Papadimitriou, A., Groner, B., and Wels, W. Recombinant antibody toxins specific for ErbB2 and EGF receptor inhibit the in vitro growth of human head and neck cancer cells and cause rapid tumor regression in vivo. Int. J. Cancer, 86: 269-275, 2000.
60. Horn, U., Strittmatter, W., Krebber, A., Knüpfer, U., Kujau, M., Wenderoth, R., Müller, K., Matzku, S., Plückthun, A., and Riesenberg, D. High volumetric yields of functional dimeric miniantibodies in Escherichia coli, using an optimized expression vector and high-cell-density fermentation under non-limited growth conditions. Appl. Microbiol. Biotechnol., 46: 524-532, 1996.
61. 111In-labeled DOTA-conjugated antibody fragments. Bioconjug. Chem., 12: 264-270, 2001.
62. 99mTechnetium-labeled single-chain Fv fragments against high molecular weight melanoma-associated antigen. Clin. Cancer Res., 6: 4921-4931, 2000.
63. Schott, M. E., Milenic, D. E., Yokota, T., Whitlow, M., Wood, J. F., Fordyce, W. A., Cheng, R. C., and Schlom, J. Differential metabolic patterns of iodinated versus radiometal chelated anticarcinoma single-chain Fv molecules. Cancer Res., 52: 6413-6417, 1992.